Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
118 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05246111 | Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) | completed | Phase 1 | 6 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 |
| Oct 1, 2024 |
| clinicaltrials |
| NCT02994953 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)(COMBO) | terminated | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 20, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT02848443 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | completed | Phase 1 | 78 | Institut de Recherches Internationales ServierOTHER | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT04675528 | Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study(FEEL) | completed | Phase 1 | 25 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT03330405 | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 223 | PfizerINDUSTRY | 9 | Oct 13, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT01772563 | Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours | completed | Phase 1 | 28 | Boehringer IngelheimINDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 4 | Aug 3, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT02986100 | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib(AME) | completed | Phase 1 | 6 | pharmaand GmbHINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03954366 | Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | completed | Phase 1 | 36 | pharmaand GmbHINDUSTRY | 3 | Jun 8, 2023 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02659020 | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma(ANNOUNCE 2) | completed | Phase 1 / Phase 2 | 310 | Eli Lilly and CompanyINDUSTRY | 10 | May 9, 2022 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | completed | Phase 1 / Phase 2 | 75 | Gilead SciencesINDUSTRY | 4 | Aug 19, 2021 | clinicaltrials |
| NCT03077607 | A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | PfizerINDUSTRY | 4 | Jun 30, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT03605212 | Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults(FLORET) | terminated | Phase 1 / Phase 2 | 30 | Menarini GroupINDUSTRY | 4 | Jun 3, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT02077933 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 8, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT01987102 | Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. | completed | Phase 1 / Phase 2 | 18 | Isofol Medical ABINDUSTRY | 4 | Sep 25, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | completed | Phase 1 / Phase 2 | 267 | Hoffmann-La RocheINDUSTRY | 10 | Jun 11, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT03057366 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | completed | Phase 1 | 8 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02106845 | Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. | completed | Phase 1 | 42 | BayerINDUSTRY | 2 | Jun 7, 2019 | clinicaltrials |
| NCT00869570 | External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 54 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT03109158 | NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 1 | NanoCarrier Co., Ltd.INDUSTRY | 4 | Apr 29, 2019 | clinicaltrials |
| NCT01145885 | BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours | completed | Phase 1 | 7 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03070548 | A Study of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | PfizerINDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT02441465 | Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials